Advaxis Chairman/CEO Thomas A. Moore to Present at the World Vaccine Congress 2010

Westfields Marriott Washington Dulles, Chantilly, VA

April 21, 2010, 4:30 PM EDT and April 22, 2010, 12:40 PM EDT

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Chairman/CEO Thomas A. Moore of Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, will be a panelist at the World Vaccine Congress 2010 tomorrow, Wednesday, April 21, 2010 at 4:30 PM EDT and Thursday, April 22, 2010 at 12:40 PM EDT.

Panels

The first panel session on Wednesday will address: “What real potential exists for vaccine antigen delivery technologies for future vaccine development?”

The second panel session on Thursday will address: “What lessons are being learned from late stage clinical studies?”

About World Vaccine Congress

Now in its 10th year, World Vaccine Congress 2010 remains the industry’s definitive vaccine industry event for major vaccine players and their respective senior level representatives. Officially, the longest-running and largest vaccine industry event in North America, World Vaccine Congress continues to deliver a forum where the ever-changing dynamics of an industry in resurgence are discussed and acted upon by the industry’s most senior figures. For more information on the list of presenting companies, please visit: http://www.terrapinn.com/2010/wvcdc/

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) immunotherapeutics that deliver engineered tumor antigens, which stimulate multiple, simultaneous, immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. The Company’s technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.



CONTACT:

Advaxis, Incorporated
Conrad F. Mir, 732-545-1590
Executive Director
732-545-1084 (FAX)
[email protected]
or
Diana Moore, 732-545-1590
Analyst
732-545-1084 (FAX)
[email protected]

KEYWORDS:   United States  North America  New Jersey  Virginia

INDUSTRY KEYWORDS:   Other Consumer  Health  Biotechnology  Pharmaceutical  Consumer

MEDIA:

Logo
 Logo

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.